GlassScriptPhysician profile
Kent J Gleed
NPI 1669449997
$15,194.43
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,597 · 2020: $1,662 · 2021: $2,578 · 2022: $1,959 · 2023: $2,228 · 2024: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Travel and Lodging: $1,788 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.12 |
| Travel and Lodging | $1,787.57 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,591.31 | 2021-2024 | Evera Mri Xt Dr Surescan, Micra, Azure Xt Dr Mri Surescan |
| Medtronic Vascular, INC. | $3,979.18 | 2019-2020 | |
| Abbott Laboratories | $2,272.88 | 2019-2024 | Ensite, Na, Viewmate |
| Boston Scientific Corporation | $1,155.13 | 2020-2024 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Impulse Dynamics (USA) INC. | $493.26 | 2022-2024 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $245.39 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.53 | 2020-2024 | Lifevest |
| Biosense Webster, INC. | $216.04 | 2019-2024 | Carto 3 |
| Merck Sharp & Dohme LLC | $159.96 | 2021-2023 | Verquvo |
| Pfizer INC. | $142.14 | 2019-2024 | |
| Amgen INC. | $141.27 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $128.32 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $119.68 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $90.29 | 2019-2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $43.48 | 2022-2024 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $35.93 | 2023 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $26.83 | 2019 | |
| Scpharmaceuticals INC. | $16.38 | 2023 | |
| Genzyme Corporation | $15.82 | 2019 | |
| Amarin Pharma, INC. | $15.78 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.09 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $13.33 | 2021 | |
| Gilead Sciences, INC. | $12.11 | 2019 | |
| Chiesi USA, INC. | $11.90 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Gleed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.